TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
äŒæ¥ã³ãŒãTELA
äŒç€ŸåTELA Bio Inc
äžå Žæ¥Nov 08, 2019
æé«çµå¶è²¬ä»»è
ãCEOãKoblish (Antony)
åŸæ¥å¡æ°209
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Nov 08
æ¬ç€Ÿæåšå°1 Great Valley Parkway, Suite 24
éœåžMALVERN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19355
é»è©±çªå·14843202930
ãŠã§ããµã€ãhttps://www.telabio.com/
äŒæ¥ã³ãŒãTELA
äžå Žæ¥Nov 08, 2019
æé«çµå¶è²¬ä»»è
ãCEOãKoblish (Antony)